Phase I/II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma Multiforme (GBM): Final Results of RTOG 0513

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized trial of bevacizumab for newly diagnosed glioblastoma.

  2014cited by this paper
• Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

  2013cited by this paper
• Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group

  2012cited by this paper
• Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study

  2012cited by this paper
• Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

  2010cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.

  2008cited by this paper
• Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.

  2007cited by this paper
• Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.

  2007cited by this paper
• Radiotherapy for glioblastoma in the elderly.

  2007cited by this paper
• Motexafin-Gadolinium Taken Up In vitro by at Least 90% of Glioblastoma Cell Nuclei

  2006cited by this paper
• Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.

  2006cited by this paper
• Motexafin Gadolinium, a Tumor-selective Drug Targeting Thioredoxin Reductase and Ribonucleotide Reductase*

  2006cited by this paper
• Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines.

  2005cited by this paper
• Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines.

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005influential reference
• Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

  2003cited by this paper
• Response criteria for phase II studies of supratentorial malignant glioma.

  1990cited by this paper

• Nanoparticles for radiooncology: Mission, vision, challenges.

  2017cites this paper